Opus, Speculum maius intitulatum

III. Speculum morale. - Sign.: a-z8, t/8, ?8, L/8, aa-ff8, gg10. - [1], 2-265, [1L. gòt. - 2 mides. - 2 col. - 74 lín. - Esp. p. inic. - Registre. - Llegendes de foli. - Filigr.: flo

Showing treatment groups, where I3C = Indole 3 carbinol; EAF = Ethyl acetate fraction; DMBA = 7, 12- dimethylbenz(α)anthracene.

<p>Showing treatment groups, where I3C  =  Indole 3 carbinol; EAF  =  Ethyl acetate fraction; DMBA  =  7, 12- dimethylbenz(α)anthracene.</p

UHPLC chromatograph of EAF.

<p>UHPLC chromatograph of EAF.</p

Effect of pharmacological interventions on hepatic enzyme activity (A) Serum glutamic oxaloacetic transaminase (B) Serum glutamic pyruvic transaminase (C) Alkaline phosphatase.

<p>a  =  p≤0.05 vs control group; b  =  p≤0.05 vs DMBA group; c  =  p≤0.05 vs I3C group; d  =  p≤0.05 vs EAF 100 group.</p

Shows TBARS, Lipid Hydroperoxide, Conjugated diene and Reduced glutathione content.

<p>Shows TBARS, Lipid Hydroperoxide, Conjugated diene and Reduced glutathione content.</p

Effect of pharmacological interventions on phase II enzymes in liver (A) Glutathione-S-transferase (B) DT-diaphorase (C) γ-Glutamyl transpeptidase.

<p>a  =  p≤0.05 vs control group; b  =  p≤0.05 vs DMBA group; c  =  p≤0.05 vs I3C group; d  =  p≤0.05 vs EAF 100 group; e  =  p≤0.05 vs EAF 200 group.</p

Percentage of polyphenolic compounds in EAF as detected by UHPLC analysis.

<p>Percentage of polyphenolic compounds in EAF as detected by UHPLC analysis.</p

Effect of pharmacological interventions on anti-oxidative enzymes in liver (A) Catalase (B) Superoxide dismutase (C) Ascorbate peroxidase (D) Glutathione reductase (E) Guiacol peroxidase (F) Lactate dehydrogenase.

<p>a  =  p≤0.05 vs control group; b  =  p≤0.05 vs DMBA group; c  =  p≤0.05 vs I3C group; d  =  p≤0.05 vs EAF 100 group; e  =  p≤0.05 vs EAF 200 group.</p

Effect of pharmacological interventions on phase I enzymes in liver (A) NADPH cytochrome P450 reductase (B) NADH cytochrome b5 reductase (C) Cytochrome P420 content (D) Cytochrome b5 content.

<p>a  =  p≤0.05 vs control group; b  =  p≤0.05 vs DMBA group; c  =  p≤0.05 vs I3C group; d  =  p≤0.05 vs EAF 100 group; e  =  p≤0.05 vs EAF 200 group.</p

Proposed functioning of Ethyl acetate fraction (EAF) as hepatoprotective agent by upregulating phase (II) enzymes against 7,12-dimethylbenz(α)anthracene (DMBA) induced hepatocarcinogenesis.

<p>Proposed functioning of Ethyl acetate fraction (EAF) as hepatoprotective agent by upregulating phase (II) enzymes against 7,12-dimethylbenz(α)anthracene (DMBA) induced hepatocarcinogenesis.</p